GSK unveils six flagship AMR research programmes powered by advanced AI

GSK and the Fleming Initiative announced six major new research programmes, called ‘Grand Challenges’ which harness some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR).

According to the recent (October 2025) WHO GLASS Report highlighting a worsening global AMR situation, around one in six laboratory confirmed bacterial infections were caused by bacteria resistant to antibiotics. Annual deaths associated with AMR are predicted to rise by 74.5% from 4.71m in 2021 to 8.22 million in 2050.

• £45m GSK funding allocated to six new research programmes combining expertise and using cutting edge AI technology to accelerate AMR research
• Leading AMR experts from Imperial College London and GSK unite to target WHO priority pathogens: Gram-negative bacteria, Aspergillus, Staph aureus (including MRSA)
• Initiative funds around 50 dedicated UK scientific and academic roles focused entirely on AMR research
• These critical projects aim to enhance understanding and advance solutions to the urgent public health threat of AMR and drug-resistant infections

Read More